License and Other AgreementsRoyalty Agreements. As of December 31, 2025, certain of our former and current officers and their affiliates held 1.13% of the future royalties. Components of Results of Operations Revenue To date, we have not recognized any revenues, including revenues from product sales. We do not expect to generate any revenue from the sale of products in the foreseeable future. If our development efforts for LB-102 or any future product candidates are successful and result in regu...
Q2 FY2026 — expected 2026-09-11
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-26 | 2025-12-31 | 0001193125-26-126368 | EDGAR | 118K words |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001193125-25-268174 | EDGAR | 73K words |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-03-26 | 0001193125-26-126223 | EDGAR | 3K words |
| 2026-03-16 | 0001193125-26-108474 | EDGAR | — |
| 2026-03-10 | 0001193125-26-099419 | EDGAR | — |
| 2026-02-05 | 0001193125-26-038539 | EDGAR | — |
| 2025-11-13 | 0001193125-25-279074 | EDGAR | — |
| 2025-11-12 | 0001193125-25-276070 | EDGAR | — |
| 2025-11-06 | 0001193125-25-268154 | EDGAR | — |
| 2025-09-12 | 0001193125-25-202195 | EDGAR | — |
13 total filings indexed. 3 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001691082 |
| Ticker | LBRX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.lbpharma.us |
| Listed | 2025-09-11 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report